Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

By L. Cherkassky, A. Morello, J. Villena-Vargas, Yang Feng, Dimiter S. Dimitrov, David R. Jones, Michel Sadelain, P. Adusumilli. Journal of Clinical Investigation, 2016

929 citations recorded by the source corpus.

Subfields: Electrical and Electronic Engineering, Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/b60a23e6abfa09d174471367d052fc8fe145a210

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Christopher S. Hackett
2. S. Rafiq
3. R. Brentjens
4. S. Albelda

In Oncology

1. Christopher S. Hackett
2. S. Rafiq
3. R. Brentjens

Citations in the corpus

• Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, methodology): “…receptor lacking intracellular signalling domains, which is able to bind to PD-L1 but is incapable of conveying inhibitory signals, resist PD- L1-induced exhaustion and prolong survival in mice bearing xenograft pleural mesotheliomas as compared with CAR T cells lacking this decoy receptor 161 .”
• Mesothelin-targeted CAR-T cell therapy for solid tumors (2020, background): “In this study, tumor cells were found to overexpress both PD-1 ligands (PD-L1, PD-L2) and tumor-infiltrating CD28 CAR-T cells isolated from progressing tumors, were found to express PD-1, TIM-3, and LAG-3 [110].”